在阿尔茨海默病中快速加速纤维瘤-1 (RAF-1) 的交叉谈话途径
Hong Hong1, Lujiao Yu1, Wenqiang Cong1
1Department of Geriatrics, The First Hospital of China Medical University, Shenyang, 110001, Liaoning, China.
Molecular neurobiology
|November 8, 2023
概括
这项研究表明,高水平的快速加速纤维瘤-1 (RAF-1) 蛋白与阿尔茨海默氏症 (AD) 病原发生有关. 像MAPK和VEGF信号传递这样的关键途径与这种关联有关.
科学领域:
- 神经科学是一个神经科学.
- 基因组学就是基因组学.
- 生物信息学是一种生物信息学.
背景情况:
- 阿尔茨海默病 (AD) 构成了全球重大健康挑战,特别是随着人口老龄化.
- 了解AD的分子基础对于开发有效的治疗策略至关重要.
研究的目的:
- 通过生物信息学分析,研究阿尔茨海默病 (AD) 中快速加速纤维瘤-1 (RAF-1) 的分子机制.
- 确定关键的信号通路和基因表达模式,与AD中高RAF-1水平相关.
主要方法:
- 在GSE132903数据集上进行了差异基因表达分析.
- 权重基因关联网络分析 (WGCNA) 用于构建全球监管网络.
- 功能性丰富分析和基因组丰富分析 (GSEA) 用于识别交叉交谈路径.
主要成果:
- 在AD和对照组之间,以及高和低RAF-1表达组之间,共确定了2700个差异表达基因 (DEG).
- 绿绿色模块中的DEGs与AD和高RAF-1密切相关,在包括血管内皮生长因子 (VEGF),神经,基激活蛋白激酶 (MAPK) 信号,氧化酸化,GABAergic突触和轴突引导在内的途径中得到丰富.
- 全球监管网络强调了MAPK,VEGF,神经营蛋白信号通路和轴突引导作为AD中的RAF-1的交叉通话通路. AUC的表现为84.2%.
结论:
- 升高的RAF-1水平与阿尔茨海默病的发病有关.
- 分子机制涉及MAPK,VEGF,神经营蛋白信号通路和轴突引导的调节.
- 与突触相关的生物过程和氧化酸化在具有高RAF-1表达和AD的个体中得到丰富.
更多相关视频
相关概念视频
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
Alzheimer's Disease: Overview
498
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
498
MAPK Signaling Cascades
5.6K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.6K
Enzyme-linked Receptors
78.6K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
78.6K
Alzheimer's Disease: Treatment
197
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
197


